NeuroSense announces shareholder letter availability
NRSN•Shareholder letter outlines PrimeC priorities and financing plans
NeuroSense Therapeutics released a CEO letter to shareholders outlining near-term priorities for PrimeC in ALS.
- FDA clearance was received to start the Phase 3 PARAGON study; planned enrollment is about 300 participants, mainly in the US.
- Financing to run PARAGON has taken longer than expected; talks continue with strategic partners, investors, grants and other non-dilutive sources.
- The company is also pursuing the Canada regulatory path, with a New Drug Submission for PrimeC targeted for December 2026 based on Phase 2b PARADIGM data.
- Nasdaq compliance efforts are focused on the bid price; board authority is being sought for a 1-for-4 to 1-for-40 reverse split if needed.
- CEO Alon Ben-Noon and CFO Or Eisenberg each invested $200,000 in April 2026; combined with another investor, the total was $600,000.
- https://www.neurosense-tx.com/
